Verition Fund Management
SRPT icon

Verition Fund Management’s Sarepta Therapeutics SRPT Stock Holding History

Verition Fund Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-112,700
Closed -$19.2M – 1761
2020
Q4 		$19.2M Buy
112,700
+39,700
+54% +$5.88M 0.17% 91
2020
Q3 		$10.3M Buy
+73,000
New +$11.1M 0.2% 78

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Verition Fund Management's SRPT Position: Q4 2025 in Review

Verition Fund Management sold out of Sarepta Therapeutics (SRPT) in Q4 2025, closing a stake of 148,367 shares — an estimated $2.86M sold.

Verition Fund Management first reported a position in SRPT in Q2 2018 and held it in 20 quarters. The position peaked at $4.71M in Q1 2025. 345 funds tracked by Wall St. Rank hold SRPT as of Q4 2025.

  • Verition Fund Management reported no remaining Sarepta Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Verition Fund Management sold 148,367 Sarepta Therapeutics shares in Q4 2025, an estimated $2.86M.
  • Verition Fund Management first reported a position in Sarepta Therapeutics in Q2 2018 and held it in 20 quarters.
  • Verition Fund Management's Sarepta Therapeutics position peaked at $4.71M in Q1 2025.
  • 345 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2025.

Based on Verition Fund Management's 13F filing for Q4 2025, filed 13 Feb 2026.